Cover Image
Market Research Report
Product code
1015841

North America Erythropoietin Drugs Market By Drug Class, By Product, By Application, By Country, Growth Potential, Industry Analysis Report and Forecast, 2021 - 2027

Published: | KBV Research | 69 Pages | Delivery time: 1-2 business days

Price

Back to Top
North America Erythropoietin Drugs Market By Drug Class, By Product, By Application, By Country, Growth Potential, Industry Analysis Report and Forecast, 2021 - 2027
Published: June 15, 2021
KBV Research
Content info: 69 Pages
Delivery time: 1-2 business days
  • ALL
  • Description
  • Table of Contents
Description

The North America Erythropoietin Drugs Market would witness market growth of 11.1% CAGR during the forecast period (2021-2027).

Erythropoietin refers to a hormone that is produced by the kidneys. It helps in the development of red blood cells in the bone marrow. The RBCs help in carrying oxygen from the lungs to the heart and then to the rest of the body. Erythropoietin drugs can be injectable in nature. They are used to cure anaemia and other blood-related diseases.

Chronic Kidney Diseases (CKD) is among the leading causes of anaemia. Therefore, the increasing incidence of CKD is the key contributing factor responsible for the growing demand for erythropoietin (EPO) drugs. According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), there are around 661,000 people who are suffering from kidney failures in the U.S. This number is likely to increase in the forecast period. This is expected to drive the demand for the market of erythropoietin drugs.

The demand for Erythropoietin Drugs is high in North America. It is due to higher awareness about erythropoietin drugs and increasing cases of renal, oncological, and anaemic diseases in this region. There is a surge in the number of patients who are suffering from chronic kidney dysfunction; this is resulting in higher demand for low-cost therapeutics. In addition, the rising awareness about erythropoietin drugs is one of the important factors accelerating the North American erythropoietin drugs market growth.

Additionally, the healthcare facilities in North America are well-established and the accessibility of infrastructure for the research is anticipated to help the growth rate of the market. The number of such advanced facilities is further expected to increase in the coming years, which is anticipated to support the North American erythropoietin drugs market. The new drug introduction with biosimilar formulations with more efficiency is anticipated to offer profitable growth possibilities to this regional market.

The US market dominated the North America Biosimilars Market by Country in 2020, and would continue to be a dominant market till 2027; thereby, achieving a market value of $4,259.9 million by 2027. The Canada market is experiencing a CAGR of 39% during (2021 - 2027). Additionally, The Mexico market would witness a CAGR of 38.1% during (2021 - 2027).

Based on Drug Class, the market is segmented into Biologics and Biosimilars. Based on Product, the market is segmented into Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa and others. Based on Application, the market is segmented into Renal Diseases, Cancer, Hematology and Neurology. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Johnson and Johnson, Teva Pharmaceuticals Industries Ltd., Amgen, Inc., F. Hoffmann-La Roche Ltd., Biocon Limited, Intas Pharmaceutical Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., LG Corporation (LG Life Sciences Ltd.), and Celltrion, Inc.

Scope of the Study

Market Segments covered in the Report:

By Drug Class

  • Biologics
  • Biosimilars

By Product

  • Epoetin-alfa
  • Epoetin-beta
  • Darbepoetin-alfa
  • others

By Application

  • Renal Diseases
  • Cancer
  • Hematology
  • Neurology

By Country

  • US
  • Canada
  • Mexico
  • Rest of North America

Companies Profiled

  • Johnson and Johnson
  • Teva Pharmaceuticals Industries Ltd.
  • Amgen, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Biocon Limited
  • Intas Pharmaceutical Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • LG Corporation (LG Life Sciences Ltd.)
  • Celltrion, Inc.

Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free
Table of Contents

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.2 Objectives
  • 1.3 Market Scope
  • 1.4 Segmentation
    • 1.4.1 North America Erythropoietin Drugs Market, by Drug Class
    • 1.4.2 North America Erythropoietin Drugs Market, by Product
    • 1.4.3 North America Erythropoietin Drugs Market, by Application
    • 1.4.4 North America Erythropoietin Drugs Market, by Country
  • 1.5 Methodology for the research

Chapter 2. Market Overview

  • 2.1 Introduction
    • 2.1.1 Overview
    • 2.1.2 Market composition and scenario
  • 2.2 Key Factors Impacting the Market
    • 2.2.1 Market Drivers
    • 2.2.2 Market Restraints

Chapter 3. North America Erythropoietin Drugs Market by Drug Class

  • 3.1 North America Biologics Market by Country
  • 3.2 North America Biosimilars Market by Country

Chapter 4. North America Erythropoietin Drugs Market by Product

  • 4.1 North America Epoetin-alfa Market by Country
  • 4.2 North America Epoetin-beta Market by Country
  • 4.3 North America Darbepoetin-alfa Market by Country
  • 4.4 North America Other Product Market by Country

Chapter 5. North America Erythropoietin Drugs Market by Application

  • 5.1 North America Renal Diseases Market by Country
  • 5.2 North America Cancer Market by Country
  • 5.3 North America Hematology Market by Country
  • 5.4 North America Neurology Market by Country

Chapter 6. North America Erythropoietin Drugs Market by Country

  • 6.1 US Erythropoietin Drugs Market
    • 6.1.1 US Erythropoietin Drugs Market by Drug Class
    • 6.1.2 US Erythropoietin Drugs Market by Product
    • 6.1.3 US Erythropoietin Drugs Market by Application
  • 6.2 Canada Erythropoietin Drugs Market
    • 6.2.1 Canada Erythropoietin Drugs Market by Drug Class
    • 6.2.2 Canada Erythropoietin Drugs Market by Product
    • 6.2.3 Canada Erythropoietin Drugs Market by Application
  • 6.3 Mexico Erythropoietin Drugs Market
    • 6.3.1 Mexico Erythropoietin Drugs Market by Drug Class
    • 6.3.2 Mexico Erythropoietin Drugs Market by Product
    • 6.3.3 Mexico Erythropoietin Drugs Market by Application
  • 6.4 Rest of North America Erythropoietin Drugs Market
    • 6.4.1 Rest of North America Erythropoietin Drugs Market by Drug Class
    • 6.4.2 Rest of North America Erythropoietin Drugs Market by Product
    • 6.4.3 Rest of North America Erythropoietin Drugs Market by Application

Chapter 7. Company Profiles

  • 7.1 Johnson and Johnson
    • 7.1.1 Company Overview
    • 7.1.2 Financial Analysis
    • 7.1.3 Segmental &Regional Analysis
    • 7.1.4 Research & Development Expenses
    • 7.1.5 Recent strategies and developments:
      • 7.1.5.1 Approvals:
  • 7.2 Teva Pharmaceutical Industries Ltd.
    • 7.2.1 Company Overview
    • 7.2.2 Financial Analysis
    • 7.2.3 Regional Analysis
    • 7.2.4 Research & Development Expenses
  • 7.3 Amgen, Inc.
    • 7.3.1 Company Overview
    • 7.3.2 Financial Analysis
    • 7.3.3 Regional Analysis
    • 7.3.4 Research & Development Expenses
    • 7.3.5 Recent strategies and developments:
      • 7.3.5.1 Partnerships, Collaborations, and Agreements:
  • 7.4 F. Hoffmann-La Roche Ltd.
    • 7.4.1 Company Overview
    • 7.4.1 Financial Analysis
    • 7.4.2 Segmental and Regional Analysis
    • 7.4.3 Research & Development Expense
  • 7.5 Biocon Limited
    • 7.5.1 Company Overview
  • 7.6 Intas Pharmaceutical Ltd.
    • 7.6.1 Company Overview
  • 7.7 Sun Pharmaceutical Industries Ltd.
    • 7.7.1 Company Overview
    • 7.7.2 Financial Analysis
    • 7.7.3 Regional Analysis
    • 7.7.4 Research & Development Expense
  • 7.8 Dr. Reddy's Laboratories Ltd.
    • 7.8.1 Company Overview
    • 7.8.2 Financial Analysis
    • 7.8.3 Segmental and Regional Analysis
    • 7.8.4 Research & Development Expense
  • 7.9 LG Corporation (LG Life Sciences Ltd.)
    • 7.9.1 Company Overview
    • 7.9.2 Financial Analysis
    • 7.9.3 Segmental and Regional Analysis
  • 7.10. Celltrion, Inc.
    • 7.10.1 Company Overview

LIST OF TABLES

  • TABLE 1 North America Erythropoietin Drugs Market, 2017 - 2020, USD Million
  • TABLE 2 North America Erythropoietin Drugs Market, 2021 - 2027, USD Million
  • TABLE 3 North America Erythropoietin Drugs Market by Drug Class, 2017 - 2020, USD Million
  • TABLE 4 North America Erythropoietin Drugs Market by Drug Class, 2021 - 2027, USD Million
  • TABLE 5 North America Biologics Market by Country, 2017 - 2020, USD Million
  • TABLE 6 North America Biologics Market by Country, 2021 - 2027, USD Million
  • TABLE 7 North America Biosimilars Market by Country, 2017 - 2020, USD Million
  • TABLE 8 North America Biosimilars Market by Country, 2021 - 2027, USD Million
  • TABLE 9 North America Erythropoietin Drugs Market by Product, 2017 - 2020, USD Million
  • TABLE 10 North America Erythropoietin Drugs Market by Product, 2021 - 2027, USD Million
  • TABLE 11 North America Epoetin-alfa Market by Country, 2017 - 2020, USD Million
  • TABLE 12 North America Epoetin-alfa Market by Country, 2021 - 2027, USD Million
  • TABLE 13 North America Epoetin-beta Market by Country, 2017 - 2020, USD Million
  • TABLE 14 North America Epoetin-beta Market by Country, 2021 - 2027, USD Million
  • TABLE 15 North America Darbepoetin-alfa Market by Country, 2017 - 2020, USD Million
  • TABLE 16 North America Darbepoetin-alfa Market by Country, 2021 - 2027, USD Million
  • TABLE 17 North America Other Product Market by Country, 2017 - 2020, USD Million
  • TABLE 18 North America Other Product Market by Country, 2021 - 2027, USD Million
  • TABLE 19 North America Erythropoietin Drugs Market by Application, 2017 - 2020, USD Million
  • TABLE 20 North America Erythropoietin Drugs Market by Application, 2021 - 2027, USD Million
  • TABLE 21 North America Renal Diseases Market by Country, 2017 - 2020, USD Million
  • TABLE 22 North America Renal Diseases Market by Country, 2021 - 2027, USD Million
  • TABLE 23 North America Cancer Market by Country, 2017 - 2020, USD Million
  • TABLE 24 North America Cancer Market by Country, 2021 - 2027, USD Million
  • TABLE 25 North America Hematology Market by Country, 2017 - 2020, USD Million
  • TABLE 26 North America Hematology Market by Country, 2021 - 2027, USD Million
  • TABLE 27 North America Neurology Market by Country, 2017 - 2020, USD Million
  • TABLE 28 North America Neurology Market by Country, 2021 - 2027, USD Million
  • TABLE 29 North America Erythropoietin Drugs Market by Country, 2017 - 2020, USD Million
  • TABLE 30 North America Erythropoietin Drugs Market by Country, 2021 - 2027, USD Million
  • TABLE 31 US Erythropoietin Drugs Market, 2017 - 2020, USD Million
  • TABLE 32 US Erythropoietin Drugs Market, 2021 - 2027, USD Million
  • TABLE 33 US Erythropoietin Drugs Market by Drug Class, 2017 - 2020, USD Million
  • TABLE 34 US Erythropoietin Drugs Market by Drug Class, 2021 - 2027, USD Million
  • TABLE 35 US Erythropoietin Drugs Market by Product, 2017 - 2020, USD Million
  • TABLE 36 US Erythropoietin Drugs Market by Product, 2021 - 2027, USD Million
  • TABLE 37 US Erythropoietin Drugs Market by Application, 2017 - 2020, USD Million
  • TABLE 38 US Erythropoietin Drugs Market by Application, 2021 - 2027, USD Million
  • TABLE 39 Canada Erythropoietin Drugs Market, 2017 - 2020, USD Million
  • TABLE 40 Canada Erythropoietin Drugs Market, 2021 - 2027, USD Million
  • TABLE 41 Canada Erythropoietin Drugs Market by Drug Class, 2017 - 2020, USD Million
  • TABLE 42 Canada Erythropoietin Drugs Market by Drug Class, 2021 - 2027, USD Million
  • TABLE 43 Canada Erythropoietin Drugs Market by Product, 2017 - 2020, USD Million
  • TABLE 44 Canada Erythropoietin Drugs Market by Product, 2021 - 2027, USD Million
  • TABLE 45 Canada Erythropoietin Drugs Market by Application, 2017 - 2020, USD Million
  • TABLE 46 Canada Erythropoietin Drugs Market by Application, 2021 - 2027, USD Million
  • TABLE 47 Mexico Erythropoietin Drugs Market, 2017 - 2020, USD Million
  • TABLE 48 Mexico Erythropoietin Drugs Market, 2021 - 2027, USD Million
  • TABLE 49 Mexico Erythropoietin Drugs Market by Drug Class, 2017 - 2020, USD Million
  • TABLE 50 Mexico Erythropoietin Drugs Market by Drug Class, 2021 - 2027, USD Million
  • TABLE 51 Mexico Erythropoietin Drugs Market by Product, 2017 - 2020, USD Million
  • TABLE 52 Mexico Erythropoietin Drugs Market by Product, 2021 - 2027, USD Million
  • TABLE 53 Mexico Erythropoietin Drugs Market by Application, 2017 - 2020, USD Million
  • TABLE 54 Mexico Erythropoietin Drugs Market by Application, 2021 - 2027, USD Million
  • TABLE 55 Rest of North America Erythropoietin Drugs Market, 2017 - 2020, USD Million
  • TABLE 56 Rest of North America Erythropoietin Drugs Market, 2021 - 2027, USD Million
  • TABLE 57 Rest of North America Erythropoietin Drugs Market by Drug Class, 2017 - 2020, USD Million
  • TABLE 58 Rest of North America Erythropoietin Drugs Market by Drug Class, 2021 - 2027, USD Million
  • TABLE 59 Rest of North America Erythropoietin Drugs Market by Product, 2017 - 2020, USD Million
  • TABLE 60 Rest of North America Erythropoietin Drugs Market by Product, 2021 - 2027, USD Million
  • TABLE 61 Rest of North America Erythropoietin Drugs Market by Application, 2017 - 2020, USD Million
  • TABLE 62 Rest of North America Erythropoietin Drugs Market by Application, 2021 - 2027, USD Million
  • TABLE 63 Key information -Johnson and Johnson
  • TABLE 64 Key Information - Teva Pharmaceuticals Industries Ltd.
  • TABLE 65 Key Information - Amgen, Inc.
  • TABLE 66 key information - F. Hoffmann-La Roche Ltd.
  • TABLE 67 Key Information - Biocon Limited
  • TABLE 68 Key Information - Intas Pharmaceutical Ltd.
  • TABLE 69 Key Information - Sun Pharmaceutical Industries Ltd.
  • TABLE 70 key information - Dr. Reddy's Laboratories Ltd.
  • TABLE 71 Key Information - LG Corporation
  • TABLE 72 key information - Celltrion, Inc.

List of Figures

  • FIG 1 Methodology for the research